Figures & data
Figure 1. Flow chart showing the two separate patient groups and study time periods. Abbreviation. TKI, tyrosine kinase inhibitor.
Table 1. Demographic and clinical characteristics of patients with advanced NSCLC who initiated TKIs as first-line therapy or as second-line therapy.
Figure 2. Mean monthly healthcare costs during the TKI treatment period for patients who initiated TKIs as first-line therapy and those who initiated it as second-line therapy. Abbreviation. TKI, tyrosine kinase inhibitor. p-values refer to comparisons of first-line and second-line TKI groups.
Table 2. Demographic and clinical characteristics of patients who received systemic anti-cancer therapy in the post-disease progression period and those who did not receive such therapy.
Figure 3. Mean monthly healthcare costs during the post-progression period for patients who received systemic anti-cancer therapy in the post-disease progression period and those who did not receive such therapy. aIncludes patients who received TKI or chemotherapy alone or in combination in the post-progression period. bIncludes patients who did not receive any systemic anti-cancer therapy in the post-progression period. Abbreviation. TKI, tyrosine kinase inhibitor. p-values refer to comparisons of treated and not treated groups.
